$3SBIO(01530)$ position gains 5,439.37 HKD with current price at 22.000 HKD versus 21.011 HKD cost basis. As a leading biopharmaceutical company in China, its innovative drug development in oncology and autoimmune diseases shows remarkable progress, with core products gaining market share. The company's long-term growth prospects remain promising as its pipeline matures and products get included in reimbursement lists.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
